Companion Diagnostics: Strategies For Biomarker Development And Early Phase Clinical Studies

By Kennon Daniels and Margaret Curnutte

Companion diagnostics (CDx) are integral to the advancement of personalized medicine, as they facilitate the identification of patients who are most likely to respond positively to specific therapeutic interventions. In this article, we will delve into the strategies for biomarker development to highlight the importance of selecting appropriate biomarkers that can accurately predict patient responses.

The list of key considerations for early-phase studies can help guide you when focusing on the methodologies and criteria for incorporating biomarkers into patient selection processes. Explore how these processes and requirements can help researchers and clinicians better navigate the intricate landscape of companion diagnostics, ultimately enhancing the precision and efficacy of personalized treatments.